藥明康德(02359.HK)：7名股東累計減持7161.93萬股A股 計劃減持數量未全部實施完畢
格隆匯11月18日丨藥明康德(02359.HK)公佈，公司於2019年8月14日披露了《無錫藥明康德新藥開發股份有限公司股東減持股份計劃公告》(公告編號：臨2019-051，以下簡稱"《股東減持計劃公告》"),Glorious Moonlight Limited、Summer Bloom Investments (I) Pte.Ltd.、嘉世康恆(天津)投資合夥企業(有限合夥)、ABG-WX Holding (HK) Limited、HCFII WX (HK) Holdings Limited、上海金藥投資管理有限公司、深圳市平安置業投資有限公司(以下合稱"減持股東")擬於2019年8月19日至2019年11月16日期間通過集中競價、大宗交易等方式減持公司A股股份。
《股東減持計劃公告》發佈後，公司於2019年9月20日完成股權激勵限制性股票回購註銷，公司總股本變更為1,637,704,965股；公司於2019年11月7日完成限制性股票授予的股份登記，公司的股份總數由1,637,704,965股增加至1,638,183,787股。
公司於2019年11月16日收到減持股東分別發送的《上市公司股東股份減持計劃實施結果的告知函》。截至減持時間區間屆滿日，減持股東就其於《股東減持計劃公告》中所披露的減持方式合計減持7161.9306萬股公司A股股份，佔公司目前總股本的4.38%，計劃減持數量未全部實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
